These include identification of BRAF target genes by comparing gene expression profiles in melanomas treated with/without BRAF inhibitors [7], screening for expression of relevant molecules to be targeted by inhibitors [8-11], and comparison of gene expression profiles of BRAFV600E vs wild-type tumors [12-13]. This evidence concerns the gene BRAF and melanoma.